Anzeige
Mehr »
Login
Mittwoch, 16.04.2025 Börsentäglich über 12.000 News von 690 internationalen Medien
Antimon bei 59.000 USD/ t - Global Tactical's Antimonminen in den USA mit 32,95 % Gehalt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von FierceBiotech

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
08.04.HHS cuts contract spend by 35%, with 334 pacts already terminated
08.04.Third Rock-backed Merida launches with $121M series A to fund autoimmune pipeline
08.04.J&J links FcRn blocker to sustained benefits as FDA ruling on potential blockbuster nears
08.04.Rallybio abandons lead program after phase 2 data in rare maternal disorder disappoint
08.04.KalVista, awaiting FDA call on HAE drug, sells Japanese rights to Kaken in $22M deal
08.04.Congressional commission urges action to maintain US biotech advantage over China
07.04.'A slow-moving catastrophe': FDA cuts are like firing all hospital staff except doctors, Janet Woodcock says
07.04.Nordic Capital steps away from potential PureTech Health buyout
07.04.Lexeo locks in pivotal trial plan as clinical data pump up prospects of cardiac gene therapy
07.04.Backing from BioNTech powers ADC specialist DualityBio toward $200M Hong Kong IPO
07.04.UK's Epsilogen acquires fellow immunoglobin biotech TigaTx to boost cancer antibody options
07.04.GSK pens $2.5B pact for ABL Bio's tech to help antibodies bypass blood-brain barrier
04.04.Trump administration faces mounting litigation as 16 states sue over NIH grant cuts
04.04.Relay Therapeutics starts third layoff wave in 1 year, shedding 70 staffers
04.04.F-star charts new path, splitting from invoX after 2023's $161M acquisition
04.04.Servier severing forces OPM to make 'drastic choices' to adapt as it cuts staff, executive wages
04.04.Apollomics tags out of TYG oncology pact to cut costs, extend runway into 2026
03.04.Cell therapy biotech Neurona nabs $102M to push epilepsy candidate into phase 3
03.04.Roche shows most Alzheimer's patients below amyloid threshold after 28 weeks
03.04.Aldeyra's dry eye drug suffers second FDA rejection, but imminent data spur hope of fast recovery
03.04.BeiGene abandons ociperlimab over poor phase 3 prospects in latest blow to TIGITs
03.04.Boehringer commits $31M to ADC R&D via new Swiss facility for NBE Therapeutics
02.04.Concentra swoops in to buy struggling Allakos, softening the blow of other denied buyout attempts
02.04.Elon Musk expected to step down from DOGE leadership role: Politico
02.04.'Patently illegal': NIH and HHS face new lawsuit over $1.1B in revoked research grants